Insider Transactions in Q4 2023 at Candel Therapeutics, Inc. (CADL)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 28
2023
|
Jason Amello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,153
-9.07%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
Francesca Barone Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,748
-9.57%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
William Garrett Nichols Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,175
-8.27%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
Paul Peter Tak Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,443
-10.42%
|
$0
$0.9 P/Share
|
|
Nov 28
2023
|
Seshu Tyagarajan Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,328
-9.05%
|
$0
$0.9 P/Share
|
|
Nov 26
2023
|
Jason Amello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,717
+36.14%
|
-
|
|
Nov 26
2023
|
Francesca Barone Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,790
+35.34%
|
-
|
|
Nov 26
2023
|
William Garrett Nichols Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,822
+37.62%
|
-
|
|
Nov 26
2023
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
104,516
+35.3%
|
-
|
|
Nov 26
2023
|
Paul Peter Tak Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,108
+30.16%
|
-
|